Basic Information
| LncRNA/CircRNA Name | PAPAS |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR |
| Sample | human TNBC cell lines, MDA-MB-157 and BT-549, Tumour and tumour-adjacent healthy tissue, Blood |
| Expression Pattern | up-regulated |
| Function Description | PAPAS was upregulated in tumour tissues of patients with TNBC versus tumouradjacent healthy tissues. Plasma PAPAS levels were also upregulated in patients with TNBC versus healthy controls. Levels of PAPAS in tumour tissue was significantly positively correlated with PAPAS levels in plasma from patients with TNBC. MiR-34a was downregulated in tumour tissues versus adjacent healthy tissues, and was significantly correlated with PAPAS in tumour tissues. PAPAS overexpression in vitro was associated with miR-34a inhibition, while miR-34a failed to significantly affect PAPAS levels. PAPAS overexpression promoted in vitro migration and invasion of TNBC cells, while miR-34a overexpression was inhibitory. MiR-34a overexpression decreased the enhanced cell migration and invasion associated with PAPAS overexpression. PAPAS overexpression showed no significant effects on cancer-cell proliferation |
| Pubmed ID | 31248310 |
| Year | 2019 |
| Title | LncRNA PAPAS may promote triple-negative breast cancer by downregulating miR-34a |
External Links
| Links for PAPAS | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |